WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).1 The Oxford Cementless Partial Knee allows surgeons to perform a PKR with improved fixation,2 better long-term implant survival rate2,3 and improved efficiency in the operating room4 (OR) compared to the Oxford Cemented Partial Knee procedure.  Following more than 20 years of clinical experience and over 300,000 procedures across Canada, Europe, Middle East, Africa, and Asia,5 the Oxford Cementless Partial Knee is now the only FDA-approved cementless partial knee implant in the U.S.

WARSAW, Ind., Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024, with a fireside chat at 8:45 a.m. ET.

A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference.

WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty.

"After the successful introduction of Persona Revision Knee in the United States and other markets, the CE Mark certification and commercial launch extends its availability significantly so that more surgeons have access to an innovative solution that can enhance patient outcomes," said Joe Urban, President, Knees at Zimmer Biomet. 

WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty.

Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World

WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster overall health and wellness.

WARSAW, Ind., Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024.  The Company reported third quarter net sales of $1.824 billion, an increase of 4.0% over the prior year period, and an increase of 4.1% on a constant currency1 basis.  Net earnings for the third quarter were $249.1 million, or $353.2 million on an adjusted1 basis.

Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System

WARSAW, Ind., Oct. 28, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS). The highly-anticipated Z1 Femoral Hip System, a triple-taper femoral system, pairs with the Company's industry-leading G7® Acetabular System to provide surgeons with a versatile, streamlined and efficient total hip arthroplasty solution. At the meeting, being held November 7-10 in Dallas, positive data on the safety and durability of the G7 Acetabular System will be presented during the poster sessions.

WARSAW, Ind., Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.

WARSAW, Ind., Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior Vice President, Investor Relations, effective September 9, 2024. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. DeMartino will be responsible for developing, refining and leading Zimmer Biomet's investor relations strategy and cultivating relationships with the investment and financial community.

WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024.

WARSAW, Ind., Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September. The team will be presenting at the Wells Fargo 2024 Healthcare Conference on Thursday, September 5, 2024, at 8:00 a.m. ET.

WARSAW, Ind., July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.